MiMedx Group, Inc.
MDXG
NASDAQ·Healthcare·Biotechnology·Mkt cap $666.1M
$4.57
▲ +3.16%
P/E
114.25
Mkt Cap
$666.1M
52-Wk Range
$3.03–$7.97
52-Week Range
$3.03 - $7.97
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 36.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary PURION processing technology preserving biological properties
- Comprehensive product portfolio across multiple healthcare applications
- Established distribution network with direct sales and independent agents
- Regulatory clearances and market presence in high-demand wound care segment
- Patented processing methods combining aseptic and terminal sterilization techniques
Bear Case
1 risk
- Average volatility.
Growth
Profitability at risk
Rising prevalence of chronic wounds and diabetic foot ulcers in aging populations
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+23.5% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MDXG right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 29, 2026
Reported EPS of -$0.05 vs -$0.05 consensus (-1.0% surprise). Revenue of $64.4M vs $63.5M expected (+1.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1.0%
Revenue trend · last 8Q
—
+7%
+4%
+13%
+35%
+27%
-33%
-35%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$84.1M
$92.9M
$88.2M
$98.6M
$113.7M
$118.1M
$59.0M
$64.4M
Margins · last 8Q
Gross
69.0%
Operating
-28.7%
Profit
-23.1%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Craig-Hallum · Aug 27, 2026
vs Industry
How MDXG stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related